Business Wire

World Parkinson’s Day 2020: BIAL launches new campaign ‘Don’t let Parkinson’s stop you. Keep on moving’

Share

BIAL Pharmaceuticals has created a new film for World Parkinson’s Day 2020 to dispel the stigma around Parkinson’s and show the amazing achievements, breadth and diversity of people living with the condition. The film, “Keep on moving”, is the latest part of a worldwide campaign, launched by BIAL four years ago. The campaign aims to increase awareness and knowledge of Parkinson's Disease and to inspire and empower millions of people living with Parkinson’s around the world.

Parkinson’s is a neurodegenerative disease that affects as many as 1.2 million people in Europe alone.1 As the disease progresses, everyday tasks such as bathing, dressing, eating, sleeping and even walking can become real challenges.2 The film aims to show that, despite this, Parkinson’s doesn’t need to define a person.

It features consecutive sets of people doing what they love, whether it be playing the guitar, drumming, drawing or cooking. One person in each set has Parkinson’s and one does not. The focus is on what makes people with Parkinson’s disease amazing rather than what makes them different. The hope is that by sharing these incredible stories it will help everyone to appreciate what people with Parkinson’s are capable of overcoming and inspire others to recognise that they are much more than their disease.

Rui Sobral, Head of BIAL’s Global Parkinson’s Department, comments: "Although Parkinson’s changes people’s lives, it’s important people don’t limit themselves or lose their self-esteem because of it. With this campaign we wanted to counter the negative portraits of people with Parkinson’s and show everyone what they can achieve. We hope the film encourages and empowers the millions of people living with Parkinson’s to never give up on pursuing their individual passions and ‘keep on moving’.”

Since 2017, BIAL has developed global campaigns associated with World Parkinson's Day to increase awareness of the disease and how it affects people directly and indirectly. The films, that have had more than 1,1 million views to date, also aim to depict how some of the limitations associated with the disease can be overcome with the understanding and support of all. Films include:

- 2020: Keep on moving
- 2019: Speak up for Parkinson's
- 2018: There's no right rhythm for life
- 2017: Me at my best

References
1. ICM Institute. Neurogenerative Diseases. Available at https://icm-institute.org/en/key-figures/. Accessed March 2020
2. Parkinson’s Foundation. Activities of Daily Living. Available at https://www.parkinson.org/Living-with-Parkinsons/Managing-Parkinsons/Activities-of-Daily-Living. Accessed March 2020

__________________________________________________________________

About BIAL
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide. For more information on BIAL: www.bial.com

About Parkinson’s Disease
Parkinson's disease is a chronic, progressive neurodegenerative disorder characterised by a strong reduction of the neurotransmitter dopamine, caused by the degeneration of certain neurons in the brain. Epidemiological evidence highlights a complex interaction between genetic vulnerability and environmental factors. The clinical manifestations usually appear after the age of 50 years (the average age of diagnosis is approximately 60 years). The prevalence of the disease is estimated at 300 per 100,000 inhabitants, increasing to 1 in 100 in the age group between 55 and 60 years. The European Parkinson's Disease Association (EPDA) estimates that approx. 1.2 million people suffer from this disease in the European Union. The diagnosis of Parkinson's disease is based on clinical observation and relies on three key elements: bradykinesia (slow movements), resting tremor, and rigidity (muscle stiffness). Of these, bradykinesia must be present, with at least either tremor or rigidity. Other common symptoms are postural instability, reduced facial expression and blinking, and a slouching posture. The disease progressively incapacitates patients, causing hindrance in their lives and daily activities.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiries
Susana Vasconcelos
T. +351 229866100 | E. susana.vasconcelos@bial.com

Grainne Maguire
T: +44 (0) 7799380801 | E. grainne@makarahealth.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LambdaTest Launches Professional Services to Elevate Quality Engineering Excellence20.9.2024 18:00:00 EEST | Press release

LambdaTest, a leading cloud-based unified testing platform, officially introduced its Professional Services, designed to transform how organizations achieve quality engineering excellence. This service offers a comprehensive suite of end-to-end testing solutions, powered by AI-driven technology, ensuring maximum test coverage, optimized test scripts, and seamless framework migrations. The newly launched services address key challenges enterprises face today—enhancing testing efficiency, increasing coverage, and reducing bottlenecks in QA. LambdaTest Professional Services also offers tailored test suite development, ensuring that organizations can craft custom solutions suited to their specific needs, while ongoing efficiency maintenance ensures long-term performance and quality. With flexible pricing plans that scale as per business needs, LambdaTest’s Professional Services are built for agility, making it easier for businesses of any size to implement robust testing frameworks and sta

Alvaria’s Workforce Enterprise Suite Becomes Aspect20.9.2024 16:00:00 EEST | Press release

Alvaria, a pioneer in workforce management and contact center customer experience technology, servicing large global enterprises and rapidly growing consumer brands, announced the rebirth of Aspect in response to accelerated company growth and a demand for more complex tools to support hybrid, remote and in-person workforces. Aspect encapsulates Alvaria’s Enterprise Workforce Suite and will operate as an Alvaria-owned subsidiary. Aspect returns to the brand portfolio with a modern and innovative suite of products, including their new next-generation platform, WorkforceOS, powered by predictive analytics and a mission to humanize the service economy. Aspect has a rich history of innovation and leadership in the contact center space, having pioneered the world’s first Automatic Call Distribution (ACD) and the first Workforce Management Software for contact centers. Alvaria has named Darryl Kelly as Chief Executive Officer to steward this brand evolution. Kelly, an accomplished senior lea

Adtran’s Coherent 100ZR and FSP 3000 OLS to play key role in OIF’s ECOC open interoperability showcase20.9.2024 15:00:00 EEST | Press release

Adtran today announced its key role in the Optical Internetworking Forum’s (OIF) demonstration of open, multi-vendor networking at the European Conference on Optical Communication (ECOC) 2024. At the center of the showcase are Adtran’s Coherent 100ZR QSFP28 pluggable module and its FSP 3000 open optical line system (OLS), which enables the transport of a wide range of data rates, including 100ZR and 400Gbit/s OpenZR+, as featured in this demo. Incorporating 100Gbit/s to 800Gbit/s coherent pluggable transceivers and various OLS technologies from multiple vendors, the demo showcases advancements in open optical networking and innovative vendor-neutral solutions, highlighting the importance of testing multi-vendor interoperability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920990844/en/ Adtran’s central role in the OIF demo underlines its commitment to developing open solutions that seamlessly interoperate with other ve

Matchday Champions , a New Class of Mobile Football Game Now Available Worldwide; Kicks off With In-Game Event Hosted by Soccer Superstar Alexia Putellas and Mega Influencer Celine Dept20.9.2024 14:00:00 EEST | Press release

Matchday, the developer of innovative mobile games for football’s five billion fans, has debuted its newest title, Matchday Champions. Today, the game is in early access globally, and it is celebrating with the limited-time “Copa Alexia x Céline,” a one-of-a-kind in-game tournament hosted by Spanish football World Cup Champion Alexia Putellas, and the immensely popular Belgian influencer Celine Dept. Backed by Lionel Messi’s Play Time fund, Alexia Putellas, and other industry legends in sports and games, Matchday Champions is a one-of-its-kind experience. The game allows players to collect, craft and manage their own dream squad made up of both men's and women's players. It delivers the excitement of football using a cutting edge narrative creation engine, ensuring no two matches are ever the same. More than two million people have already pre-registered ahead of launch. Matchday Champions is now available in early access globally for iOS and Android phones. Players who download the ga

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy20.9.2024 11:12:00 EEST | Press release

Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of Duchenne muscular Dystrophy (DMD). These designations would help take the progress in pre-clinical and clinical studies conducted in Japan and India to clinical trials in the USA, for approval by FDA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920153092/en/ The parable of the lost sheep mirrors our journey to find a solution for Duchenne Muscular Dystrophy (DMD), a rare disease. Our global interdisciplinary team is fortunate to have been gifted with Neu REFIX, whose hidden potentials of beneficial immune modulation, we unravelled by extensive preclinical and clinical studies. This gives hope to DMD patients for its potentials in improving their quality of life by halting the disease progress. Like the shepherd when he fou

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye